| 28/05/26 | 07:00:03 | 28 May 2026 | | Half Year Report |
| 31/03/26 | 07:00:01 | 31 Mar 2026 | | Total Voting Rights |
| 11/03/26 | 07:00:07 | 11 Mar 2026 | | £1.0 million Placing |
| 10/03/26 | 07:00:11 | 10 Mar 2026 | | Confirmation of US ODD for NXP002 in IPF |
| 03/03/26 | 10:05:00 | 3 Mar 2026 | | Result of AGM |
| 05/02/26 | 12:00:00 | 5 Feb 2026 | | Posting of Annual Report and Notice of AGM |
| 27/01/26 | 07:00:06 | 27 Jan 2026 | | Annual Results for period ended 30 September 2025 |
| 28/11/25 | 15:22:23 | 28 Nov 2025 | | Total Voting Rights |
| 12/11/25 | 07:01:00 | 12 Nov 2025 | | Update re. US FDA ODD Application |
| 12/11/25 | 07:00:09 | 12 Nov 2025 | | Results of Underwritten Open Offer |
| 28/10/25 | 07:00:07 | 28 Oct 2025 | | Underwritten Open Offer |
| 10/10/25 | 07:00:10 | 10 Oct 2025 | | Change of Auditor |
| 25/09/25 | 07:00:13 | 25 Sept 2025 | | European Respiratory Society Congress Attendance |
| 11/08/25 | 07:00:09 | 11 Aug 2025 | | US FDA ODD Application Submitted for NXP002 |
| 30/05/25 | 14:24:44 | 30 May 2025 | | Total Voting Rights |
| 29/05/25 | 07:00:08 | 29 May 2025 | | Confirmation of European ODD for NXP002 |
| 23/05/25 | 13:08:06 | 23 May 2025 | | Publication of a Prospectus |
| 22/05/25 | 07:00:07 | 22 May 2025 | | £210,000 Placing |
| 19/05/25 | 07:00:09 | 19 May 2025 | | Attendance at American Thoracic Society Congress |
| 02/05/25 | 07:00:04 | 2 May 2025 | | Half-year Report |
| 30/04/25 | 07:00:09 | 30 Apr 2025 | | Confirmation of European Orphan Drug Designation |
| 29/04/25 | 07:00:08 | 29 Apr 2025 | | Change of Registered Office and Company Secretary |
| 14/04/25 | 07:00:09 | 14 Apr 2025 | | Exercise of Warrants |
| 09/04/25 | 07:00:04 | 9 Apr 2025 | | NXP002 Update |
| 20/03/25 | 11:10:07 | 20 Mar 2025 | | Result of AGM |
| 28/02/25 | 12:30:10 | 28 Feb 2025 | | Total Voting Rights |
| 14/02/25 | 14:18:06 | 14 Feb 2025 | | Posting of Annual Report and Notice of AGM |
| 30/01/25 | 07:00:07 | 30 Jan 2025 | | £168,750 Placing |
| 29/01/25 | 07:00:05 | 29 Jan 2025 | | Annual Results for period ended 30 September 2024 |
| 28/01/25 | 07:00:04 | 28 Jan 2025 | | NXP002 ODD Application Submitted |
| 13/01/25 | 07:00:04 | 13 Jan 2025 | | NXP002 Orphan Drug Designation Draft Application |
| 29/11/24 | 17:00:01 | 29 Nov 2024 | | Total Voting Rights |
| 05/11/24 | 14:25:25 | 5 Nov 2024 | | Director/PDMR Dealings |
| 04/11/24 | 10:17:46 | 4 Nov 2024 | | Result of General Meeting |
| 16/10/24 | 13:37:55 | 16 Oct 2024 | | Publication of Prospectus & Notice of GM |
| 20/09/24 | 14:24:52 | 20 Sept 2024 | | £300,000 Fundraise |
| 18/06/24 | 07:00:07 | 18 Jun 2024 | | Half-year Report |
| 17/06/24 | 07:00:08 | 17 Jun 2024 | | Patent Update |
| 19/03/24 | 14:39:02 | 19 Mar 2024 | | Result of AGM |
| 01/03/24 | 07:00:04 | 1 Mar 2024 | | Subscription to raise £150,000 |
| 15/01/24 | 11:30:00 | 15 Jan 2024 | | Posting of Annual Report and Notice of AGM |
| 03/01/24 | 07:00:04 | 3 Jan 2024 | | Results for the period ended 30 September 2023 |
| 18/12/23 | 07:00:10 | 18 Dec 2023 | | NXP001 Update |
| 23/10/23 | 07:00:11 | 23 Oct 2023 | | Notice of Allowance of NXP002 Patent in Japan |
| 18/09/23 | 07:00:05 | 18 Sept 2023 | | NXP001 Update |
| 24/08/23 | 13:22:39 | 24 Aug 2023 | | Result of Annual General Meeting |
| 31/07/23 | 14:00:01 | 31 Jul 2023 | | Notice of AGM |
| 26/07/23 | 14:55:00 | 26 Jul 2023 | | Holding(s) in Company |
| 02/06/23 | 07:00:06 | 2 Jun 2023 | | Investor Online Q&A |
| 25/05/23 | 07:00:10 | 25 May 2023 | | Change of Auditor |
